'At this stage of the pandemic, data supports simplifying the use' of the Pfizer and Moderna vaccines, FDA vaccine chief Dr. Peter Marks said
In a long-awaited move, an FDA advisory panel decided to do away with the confusion surrounding COVID-19 shots and boosters.U.S. regulators on Tuesday cleared another COVID-19 booster dose for older adults and people with weak immune systems so they can shore up protection this spring - while taking steps to make coronavirus vaccinations simpler for everyone else.
Anyone who's gotten their original vaccinations but hasn't yet had an omicron-targeted booster can still get one - but the agency will decide over the summer if younger, healthy people will eventually be offered a second bivalent booster. The Pfizer and Moderna boosters contain protection against both the original coronavirus strain and omicron versions known as BA.4 and BA.5. While newer omicron cousins now are circulating, recent studies show the bivalent shots still are effective.
But at least 250 people in the U.S. a day still die from COVID-19, many of them elderly or frail, and protection can wane.For eligible, high-risk groups, a spring second booster is a reasonable choice, said Dr. Matthew Laurens of the University of Maryland School of Medicine.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Supreme Court to Decide Future of Abortion Pill MifepristoneWATCH: The FDA approved mifepristone initially some 20 years ago, but now the question is whether the FDA did it the right way, says legal analyst Dan Eaton.
Weiterlesen »
Single Dose of Omicron-Targeting Vaccines to Become Main Covid-19 Shot in U.S.Americans seeking messenger RNA vaccines for Covid-19 for the first time will get one shot targeting both the Omicron variant and the original strain of the virus
Weiterlesen »
Abortion-pill rulings could break the FDA, drug companies sayPharmaceutical companies have mobilized against a pair of lower-court rulings restricting access to abortion pills that they contend go far beyond issues of reproductive health and pose a threat to the regulatory foundations of the U.S. drug industry.
Weiterlesen »
Moderna/Merck cancer vaccine plus Keytruda delays skin cancer returnAn experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.
Weiterlesen »
Moderna cancer vaccine with Merck's Keytruda delays return of deadly skin cancerModerna cancer vaccine with Merck’s Keytruda delays return of deadly skin cancer
Weiterlesen »
Sen. Cassidy dismisses Democrats’ concerns over FDA authority after abortion pill rulingSen. Bill Cassidy on Sunday described fears by Democrats that a court ruling against the abortion pill mifepristone could uproot the Food and Drug Administration’s approval of other drugs as vastly exaggerated.
Weiterlesen »